

Laboratorio Reig Jofre SA RJF

Last Close
0.21

Quantitative Fair Value Estimate
0.25

Market Cap (Mil)
264.6

Sector
Healthcare


Industry
Drug Manufacturers - Specialty & Generic

Country of Domicile
Spain

Laboratorio Reig Jofre SA is engaged in the development of prescription and non-prescription pharmaceutical products, medical devices, nutritional supplements and consumer healthcare products.

Quantitative Scores

		Scores		
		All	Rel Sector	Rel Country
Quantitative Moat	None	53	62	37
Valuation	Undervalued	55	52	73
Quantitative Uncertainty	Very High	73	74	57
Financial Health	Moderate	45	26	32




Valuation

	Current	5-Yr Avg	Sector Median	Country Median
Price/Quant Fair Value	0.85	0.92	0.85	0.92
Price/Earnings	1.2	41.9	27.7	16.6
Forward P/E	—	—	13.4	13.5
Price/Cash Flow	—	186.7	18.7	8.6
Price/Free Cash Flow	—	1.1	27.3	16.4
Dividend Yield %	—	—	1.48	2.79
Price/Book	2.2	1.0	3.4	1.5
Price/Sales	0.6	2.0	4.0	1.2

Profitability

	Current	5-Yr Avg	Sector Median	Country Median
Return on Equity %	10.7	-0.2	12.4	9.5
Return on Assets %	8.0	0.4	6.5	3.2
Revenue/Employee (K)	146.2	226.6	300.9	279.9

Quantitative Moat




Financial Health

	Current	5-Yr Avg	Sector Median	Country Median
Distance to Default	0.5	0.5	0.6	0.6
Solvency Score	—	—	510.5	608.5
Assets/Equity	1.5	1.6	1.4	2.7
Long-Term Debt/Equity	0.0	0.1	0.1	0.4

Growth Per Share

	1-Year	3-Year	5-Year	10-Year
Revenue %	85.0	25.3	-15.5	9.6
Operating Income %	156.5	—	—	5.0
Earnings %	5,898.2	52.7	—	26.7
Dividends %	—	—	—	—
Book Value %	-59.8	-29.1	-19.9	-2.2
Stock Total Return %	-11.8	17.1	-7.8	-14.5

Price Versus Quantitative Fair Value



	2010	2011	2012	2013	2014	TTM	Financials (Fiscal Year in K)
Revenue	38,841	29,485	29,926	31,370	58,036	121,494	Revenue
% Change	-71.1	-24.1	1.5	4.8	85.0	109.3	% Change
Operating Income	-19,166	-16,676	128	2,014	5,165	11,786	Operating Income
% Change	—	—	—	1,473.4	156.4	128.2	% Change
Net Income	-22,618	16,066	-6	953	4,833	10,788	Net Income
Operating Cash Flow	-5,024	-7,110	-5,892	396	—	396	Operating Cash Flow
Capital Spending	-988	-641	-486	-482	—	-482	Capital Spending
Free Cash Flow	-6,012	-7,751	-6,378	-86	—	-86	Free Cash Flow
% Sales	-15.5	-26.3	-21.3	-0.3	—	-0.1	% Sales
EPS	-0.07	0.05	0.00	0.00	0.18	0.18	EPS
% Change	—	—	-100.0	—	5,822.7	1.3	% Change
Free Cash Flow/Share	-0.09	-0.02	-0.02	-0.01	0.00	0.00	Free Cash Flow/Share
Dividends/Share	—	—	—	0.04	0.00	0.00	Dividends/Share
Book Value/Share	0.37	0.23	0.26	0.24	0.06	0.10	Book Value/Share
Shares Outstanding (Mil)	329	329	324	1,260	—	1,260	Shares Outstanding (Mil)
Profitability							Profitability
Return on Equity %	-27.1	20.1	0.0	1.2	5.0	10.7	Return on Equity %
Return on Assets %	-11.8	9.2	0.0	1.1	3.7	8.0	Return on Assets %
Net Margin %	-58.2	54.5	0.0	3.0	8.3	8.9	Net Margin %
Asset Turnover	0.20	0.17	0.23	0.35	0.44	0.90	Asset Turnover
Financial Leverage	2.5	1.9	1.1	1.1	1.5	1.5	Financial Leverage
Gross Margin %	73.2	83.3	73.1	73.9	64.7	62.9	Gross Margin %
Operating Margin %	-49.3	-56.6	0.4	6.4	8.9	9.7	Operating Margin %
Long-Term Debt	205	17,656	0	—	5,806	5,167	Long-Term Debt
Total Equity	73,354	86,590	86,753	75,617	118,144	125,130	Total Equity
Fixed Asset Turns	11.4	62.1	99.9	135.2	4.8	9.4	Fixed Asset Turns

Quarterly Revenue & EPS

Revenue (K)	Mar	Jun	Sep	Dec	Total
2015	42,999.0	38,194.6	—	—	—
2014	10,096.0	7,640.0	7,016.0	33,284.4	58,036.4
2013	10,741.0	7,418.0	7,143.0	6,068.0	31,370.0
2012	9,466.0	7,393.0	6,732.0	13,067.0	29,926.0
Earnings Per Share					
2015	0.00	0.00	—	—	—
2014	0.01	0.00	0.00	0.17	0.18
2013	0.01	0.00	0.00	0.00	0.00
2012	0.01	-0.04	0.03	0.03	0.00

Revenue Growth Year On Year %

